COMMUNIQUÉS West-GlobeNewswire

Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session
16/03/2026
MONTREAL and CHARLOTTE, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular [...]
Prodeon Medical Receives FDA 510(k) Clearance for the Urocross® Expander System, a Novel Non-Permanent Retrievable Implant for Treating Urinary Symptoms Associated with Benign Prostatic Hyperplasia
16/03/2026
The Urocross® Expander System is designed to remodel the obstructing prostatic lobes during the six-month indwell time and is intentionally retrieved, leaving no permanent foreign material behind. SUNNYVALE, Calif., [...]
Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update
16/03/2026
-- Recorded Fourth Quarter Revenues of $35.7 Million and Transition Period Revenues of $75.5 Million -- -- Multiple New Programs Signed in Fourth Quarter 2025 Including Two Commercial Site Transfer Programs, for Total [...]
vTv Therapeutics to Participate in the 38th Annual ROTH Conference
16/03/2026
HIGH POINT, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin , a novel, potential first-in-class oral [...]
Merit Medical Launches the Resilience Through-the-Scope Esophageal Stent
16/03/2026
New Resilience™ deployment system, anti-migration stent design, and unique stent sizes offer physicians control while enhancing treatment for patients with esophageal fistulas and malignant strictures SOUTH JORDAN, Utah [...]
Completion of Share Buy-back Program
16/03/2026
Company Announcement COPENHAGEN, Denmark; March 16, 2026 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 13, 2026. On February 17, 2026, Genmab announced the initiation [...]
Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation
16/03/2026
RESEARCH TRIANGLE PARK, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement with Cipla [...]
Nadia Care Raises $12 Million to Expand Community-Centered Maternal Care Model Across the U.S.
16/03/2026
Expansion in DC, Maryland, and Tennessee Markets on the Heels of Excellent Outcomes WASHINGTON, March 16, 2026 (GLOBE NEWSWIRE) -- Nadia Care, the maternal health company formerly known as Cayaba Care, announced a $12 [...]
Solve GNE Highlights New Research, Expands Funding Efforts, and Advances Toward a Phase I Clinical Trial for GNE Myopathy
16/03/2026
LOS ANGELES, March 16, 2026 (GLOBE NEWSWIRE) -- Solve GNE, a nonprofit foundation dedicated to accelerating treatments for GNE myopathy, has announced major progress across its research, fundraising, and regulatory [...]
Flyte Launches Florida Hops to Service Accelerating Demand
16/03/2026
Fleet Expansion Underway With Five Vision Jets Expected to Be Operating by Memorial Day Regional Aviation Platform Now Connects Entire East Coast Following Successful Soft Launch in Florida FORT MILL, S.C., March 16, [...]
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
16/03/2026
TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company [...]
Qolab Announces John Martinis Prize as Momentum Builds for Scalable Quantum Hardware
16/03/2026
Debuting at APS Global Physics Summit with Quantum Machines and IQCC, Alongside New Collaborations, Education Programs, and Hiring Expansion DENVER, March 16, 2026 (GLOBE NEWSWIRE) -- Qolab today announced the launch of [...]
Novonesis issues EUR 1.7 billion in bonds to refinance bridge facility
16/03/2026
COPENHAGEN, Denmark – March 16, 2026 . Novonesis has completed a EUR 1.7 billion bond issuance, with significant interest from a broad group of investors. The transaction was primarily undertaken to refinance the bridge [...]
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth
16/03/2026
• Extends the budget period for the ~$2M total NIH grant funding award for DARE-PTB1 through November 2026 • DARE-PTB1 targets preterm birth, for which there are no FDA-approved treatment options • Award reflects Daré's [...]
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
16/03/2026
Early clinical proof-of-concept for WEE1 inhibitor APR-1051 in the ongoing ACESOT-1051 trial with two partial responders at first scan in endometrial cancer patients with PPP2R1A mutation Clinical team strengthened with [...]
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026
16/03/2026
Recruitment for the rheumatoid arthritis (RA) sub-study of the SKYWAY basket trial is complete; Week 12 topline data now expected in Q3 2026 Recruitment for the psoriatic arthritis (PsA) and axial spondyloarthritis ( [...]
Heartflow Builds Evidence Base Across the Heart Disease Care Continuum, From Precision Risk Stratification to CT-Guided Intervention Planning
16/03/2026
Three presentations at ACC reinforce Heartflow’s AI-powered technology predicts MACE, drives superior lipid outcomes and results in cost-effective care First patient enrolled in p ioneering N AVIGATE - PCI Registry [...]
Herantis Pharma to present HER-096 Phase 1b data at International Conference on Alzheimer’s & Parkinson’s Diseases
16/03/2026
Espoo, Finland, March 16, 2026: Herantis Pharma Plc ("Herantis"), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, announces that its Chief Scientific [...]
George Medicines extends global commercialization of GMRx2 into Australia and New Zealand with Arrotex licensing agreement
16/03/2026
Arrotex gains exclusive rights in Australia and New Zealand to innovative single pill combination of three hypertension medicines, including two doses that are lower than those currently available in single pill [...]

Pages